BRPI0919581A2 - métodos para reduzir a disponibilidade de células procarióticas, para aumentar suscetibilidade antibiótica procariótica, para tratar infecção bacteriana em um paciente, e para exterminar bactérias, inibir o desenvolvimento bacteriano ou reduzir a virulência bacteriana, polinucleotídeo isca, célula, usos de um polinucleotídeo isca, e de isca de fator de transição, composição farmacêutica, composição de limpeza, kit, e, isca de fator de transição. - Google Patents
métodos para reduzir a disponibilidade de células procarióticas, para aumentar suscetibilidade antibiótica procariótica, para tratar infecção bacteriana em um paciente, e para exterminar bactérias, inibir o desenvolvimento bacteriano ou reduzir a virulência bacteriana, polinucleotídeo isca, célula, usos de um polinucleotídeo isca, e de isca de fator de transição, composição farmacêutica, composição de limpeza, kit, e, isca de fator de transição.Info
- Publication number
- BRPI0919581A2 BRPI0919581A2 BRPI0919581A BRPI0919581A BRPI0919581A2 BR PI0919581 A2 BRPI0919581 A2 BR PI0919581A2 BR PI0919581 A BRPI0919581 A BR PI0919581A BR PI0919581 A BRPI0919581 A BR PI0919581A BR PI0919581 A2 BRPI0919581 A2 BR PI0919581A2
- Authority
- BR
- Brazil
- Prior art keywords
- bait
- polynucleotide
- reducing
- transition factor
- bacterial
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10241408P | 2008-10-03 | 2008-10-03 | |
| PCT/GB2008/003353 WO2009044154A2 (en) | 2007-10-03 | 2008-10-03 | Transcription factor decoys, compositions and methods |
| US16759209P | 2009-04-08 | 2009-04-08 | |
| GBGB0906130.0A GB0906130D0 (en) | 2008-10-03 | 2009-04-08 | Transcription factor decoys |
| PCT/GB2009/051301 WO2010038083A2 (en) | 2008-10-03 | 2009-10-02 | Transcription factor decoys |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0919581A2 true BRPI0919581A2 (pt) | 2015-12-08 |
Family
ID=40750813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0919581A BRPI0919581A2 (pt) | 2008-10-03 | 2009-10-02 | métodos para reduzir a disponibilidade de células procarióticas, para aumentar suscetibilidade antibiótica procariótica, para tratar infecção bacteriana em um paciente, e para exterminar bactérias, inibir o desenvolvimento bacteriano ou reduzir a virulência bacteriana, polinucleotídeo isca, célula, usos de um polinucleotídeo isca, e de isca de fator de transição, composição farmacêutica, composição de limpeza, kit, e, isca de fator de transição. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20110251264A1 (pt) |
| EP (1) | EP2334819B1 (pt) |
| JP (3) | JP2012504411A (pt) |
| KR (1) | KR20110084213A (pt) |
| CN (1) | CN102292453A (pt) |
| AU (2) | AU2009299552A1 (pt) |
| BR (1) | BRPI0919581A2 (pt) |
| CA (1) | CA2738743A1 (pt) |
| ES (1) | ES2444640T3 (pt) |
| GB (1) | GB0906130D0 (pt) |
| IL (1) | IL211846A (pt) |
| MX (1) | MX2011003582A (pt) |
| NZ (1) | NZ591594A (pt) |
| RU (1) | RU2011117228A (pt) |
| SG (1) | SG191684A1 (pt) |
| WO (1) | WO2010038083A2 (pt) |
| ZA (1) | ZA201102118B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0719367D0 (en) | 2007-10-03 | 2007-11-14 | Procarta Biosystems Ltd | Transcription factor decoys, compositions and methods |
| GB201002413D0 (en) | 2010-02-12 | 2010-03-31 | Procarta Biosystems Ltd | Nucleic acid complexes |
| GB201005545D0 (en) * | 2010-04-01 | 2010-05-19 | Procarta Biosystems Ltd | Transcription factor decoys |
| WO2014140581A1 (en) * | 2013-03-13 | 2014-09-18 | Procarta Biosystems Ltd | Transcription factor decoys |
| SG11201608486SA (en) * | 2014-04-11 | 2016-11-29 | Redvault Biosciences Lp | Systems and methods for clonal replication and amplification of nucleic acid molecules for genomic and therapeutic applications |
| RU2017108238A (ru) * | 2014-08-15 | 2018-09-17 | Эйдинкс, Инк. | Олигонуклеотиды-приманки для лечения боли |
| CN106188302A (zh) * | 2015-05-08 | 2016-12-07 | 复旦大学 | YycG-PAS单克隆抗体及其用途 |
| JP7034951B2 (ja) | 2016-06-08 | 2022-03-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 操作されたウイルスベクターは炎症および免疫応答の誘導を低減する |
| JP2021502381A (ja) | 2017-11-08 | 2021-01-28 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ウイルスベクター誘発性炎症反応を阻害するための組成物および方法 |
| EP4017983A4 (en) | 2019-08-22 | 2023-08-23 | National University of Singapore | METHOD FOR GENERATION OF DUMBBELL-SHAPED DNA VECTORS |
| CN110484484A (zh) * | 2019-08-29 | 2019-11-22 | 西北农林科技大学 | 一株布鲁氏菌S2疫苗株ArsR基因缺失菌株、其构建方法及应用 |
| CN111197019B (zh) * | 2020-01-10 | 2022-04-15 | 安徽大学 | 一种通过糖多孢红霉菌sace_1906基因途径提高红霉素产量的方法 |
| CN111944874B (zh) * | 2020-07-20 | 2023-06-30 | 广东省微生物研究所(广东省微生物分析检测中心) | 一种筛选鉴定胁迫应答基因表达调控因子的方法 |
| CN113073073A (zh) * | 2021-04-08 | 2021-07-06 | 四川大学华西医院 | 粪肠球菌突变菌、粪肠球菌感染的治疗药物以及应用 |
| WO2024167937A1 (en) * | 2023-02-08 | 2024-08-15 | Qpex Biopharma, Inc. | Methods for the determination of susceptibility of siderophore beta-lactams |
| CN119746072A (zh) * | 2024-12-18 | 2025-04-04 | 浙江大学 | 莫拉氏菌科中的全局性胁迫响应元件DdaA的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6637394A (en) * | 1993-04-19 | 1994-11-08 | Medisorb Technologies International L.P. | Long-acting treatment by slow-release delivery of antisense oligodeoxyribonucleotides from biodegradable microparticles |
| EP1210365A2 (en) * | 1999-08-17 | 2002-06-05 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for restoring antibiotic susceptibility in glycopeptide-resistant enterococcus |
| US7294504B1 (en) * | 2001-12-27 | 2007-11-13 | Allele Biotechnology & Pharmaceuticals, Inc. | Methods and compositions for DNA mediated gene silencing |
| ATE556714T1 (de) * | 2002-02-01 | 2012-05-15 | Life Technologies Corp | Doppelsträngige oligonukleotide |
| CN1240439C (zh) * | 2002-03-28 | 2006-02-08 | 南京凯基生物科技发展有限公司 | 肿瘤基因开关药物 |
| US20070014840A1 (en) * | 2002-04-26 | 2007-01-18 | In-Kyu Lee | Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription |
| ATE516366T1 (de) * | 2002-07-25 | 2011-07-15 | Archemix Corp | Regulierte aptamer-therapeutika |
| WO2004016754A2 (en) * | 2002-08-14 | 2004-02-26 | Pharmacia Corporation | ANTISENSE MODULATION OF Nav1.3 EXPRESSION |
| EP1629124A2 (en) * | 2003-06-05 | 2006-03-01 | Wyeth | Nucleic acid arrays for detecting multiple strains of a non-viral species |
| EP1691817A2 (en) * | 2003-12-02 | 2006-08-23 | Corgentech, Inc. | NF-kB OLIGONUCLEOTIDE DECOY MOLECULES |
| ES2385485T3 (es) * | 2003-12-03 | 2012-07-25 | Abbott Laboratories | Sonda de ácido nucleico lineal de doble hebra y usos de la misma |
| US8372966B2 (en) * | 2003-12-19 | 2013-02-12 | University Of Cincinnati | Oligonucleotide decoys and methods of use |
| WO2006096140A1 (en) * | 2005-03-10 | 2006-09-14 | Agency For Science, Technology And Research | Methods for assessing suitability of cancer patients for treatment with histone deacetylase inhibitors |
| US7811809B2 (en) * | 2005-06-15 | 2010-10-12 | Saint Louis University | Molecular biosensors for use in competition assays |
| AU2006279906B2 (en) * | 2005-08-10 | 2012-05-10 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| CA2634987C (en) * | 2006-01-17 | 2017-01-03 | Somalogic, Inc. | Multiplexed analyses of test samples |
| US20110021600A1 (en) * | 2006-09-04 | 2011-01-27 | Kyowa Hakko Kirin Co., Ltd. | Novel nucleic acid |
| JPWO2008084319A1 (ja) * | 2006-12-18 | 2010-04-30 | 協和発酵キリン株式会社 | 新規核酸 |
| GB201002413D0 (en) * | 2010-02-12 | 2010-03-31 | Procarta Biosystems Ltd | Nucleic acid complexes |
-
2009
- 2009-04-08 GB GBGB0906130.0A patent/GB0906130D0/en not_active Ceased
- 2009-10-02 RU RU2011117228/10A patent/RU2011117228A/ru not_active Application Discontinuation
- 2009-10-02 US US13/062,922 patent/US20110251264A1/en not_active Abandoned
- 2009-10-02 ES ES09785723.9T patent/ES2444640T3/es active Active
- 2009-10-02 BR BRPI0919581A patent/BRPI0919581A2/pt not_active IP Right Cessation
- 2009-10-02 MX MX2011003582A patent/MX2011003582A/es not_active Application Discontinuation
- 2009-10-02 SG SG2013047139A patent/SG191684A1/en unknown
- 2009-10-02 WO PCT/GB2009/051301 patent/WO2010038083A2/en not_active Ceased
- 2009-10-02 AU AU2009299552A patent/AU2009299552A1/en not_active Abandoned
- 2009-10-02 KR KR1020117010205A patent/KR20110084213A/ko not_active Ceased
- 2009-10-02 NZ NZ591594A patent/NZ591594A/xx not_active IP Right Cessation
- 2009-10-02 EP EP09785723.9A patent/EP2334819B1/en not_active Not-in-force
- 2009-10-02 JP JP2011529635A patent/JP2012504411A/ja active Pending
- 2009-10-02 CA CA2738743A patent/CA2738743A1/en not_active Abandoned
- 2009-10-02 CN CN2009801486387A patent/CN102292453A/zh active Pending
-
2011
- 2011-03-22 ZA ZA2011/02118A patent/ZA201102118B/en unknown
- 2011-03-22 IL IL211846A patent/IL211846A/en not_active IP Right Cessation
-
2015
- 2015-05-27 JP JP2015107110A patent/JP2015231368A/ja active Pending
-
2016
- 2016-04-04 AU AU2016202080A patent/AU2016202080A1/en not_active Abandoned
-
2017
- 2017-07-14 JP JP2017137691A patent/JP2018023367A/ja not_active Ceased
-
2018
- 2018-03-13 US US15/920,279 patent/US20180265915A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2334819A2 (en) | 2011-06-22 |
| WO2010038083A3 (en) | 2010-06-10 |
| MX2011003582A (es) | 2011-08-12 |
| ZA201102118B (en) | 2013-08-28 |
| ES2444640T3 (es) | 2014-02-26 |
| NZ591594A (en) | 2013-07-26 |
| AU2016202080A1 (en) | 2016-04-28 |
| SG191684A1 (en) | 2013-07-31 |
| CA2738743A1 (en) | 2010-04-08 |
| CN102292453A (zh) | 2011-12-21 |
| GB0906130D0 (en) | 2009-05-20 |
| AU2009299552A1 (en) | 2010-04-08 |
| JP2012504411A (ja) | 2012-02-23 |
| JP2015231368A (ja) | 2015-12-24 |
| RU2011117228A (ru) | 2012-11-10 |
| IL211846A (en) | 2015-07-30 |
| US20110251264A1 (en) | 2011-10-13 |
| JP2018023367A (ja) | 2018-02-15 |
| EP2334819B1 (en) | 2013-10-30 |
| US20180265915A1 (en) | 2018-09-20 |
| KR20110084213A (ko) | 2011-07-21 |
| IL211846A0 (en) | 2011-06-30 |
| WO2010038083A2 (en) | 2010-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0919581A2 (pt) | métodos para reduzir a disponibilidade de células procarióticas, para aumentar suscetibilidade antibiótica procariótica, para tratar infecção bacteriana em um paciente, e para exterminar bactérias, inibir o desenvolvimento bacteriano ou reduzir a virulência bacteriana, polinucleotídeo isca, célula, usos de um polinucleotídeo isca, e de isca de fator de transição, composição farmacêutica, composição de limpeza, kit, e, isca de fator de transição. | |
| EP2303183A4 (en) | SURGICAL SUTURES INCORPORATED IN STEM CELLS OR OTHER BIOACTIVE MATERIALS | |
| BRPI0811193A2 (pt) | Proteína de ligação a antígeno isolada, ácido nucleico, célula recombinante, métodos para produzir uma proteína e para proteger ou tratar contra uma infecção por s. aureus em paciente, composição farmacêutica, uso da proteína de ligação a antígeno, e, polipeptídeo. | |
| WO2010090860A3 (en) | Methods and compositions for treating bacterial infection | |
| BRPI0813450A2 (pt) | Composto, composição, combinação, formulação farmacêutica, e, métodos para inibir uma enzima, para exterminar ou prevenir o crescimento de um microorganismo e para tratar e/ou prevenir uma doença em um animal | |
| BRPI0906549A2 (pt) | Bandagens médicas com válvulas e kits contendo as mesmas. | |
| BRPI1007602A2 (pt) | "anticorpo tri ou tetraespecífico, método para preparação de um anticorpo triespecífico ou tetraespecífico, célula hospedeira, composição, composição farmacêutica e método para o tratamento de um paciente com necessidade de terapia" | |
| CL2007003472A1 (es) | Sal fumarato de (alfa s,beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamie | |
| IL202386A0 (en) | Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis | |
| BRPI0812473A2 (pt) | Composto, composição farmacêutica, métodos para inibir dna girase bacteriana e/ou topoisomerase iv bacteriana em um animal de sangue quente em necessidade de tal tratamento, para produzir um efeito antibacteriano em um animal de sangue quente em necessidade de tal tratamento, e para tratar uma infecção bacteriana em um animal de sangue quente em necessidade do mesmo, uso de um composto, e, processo para preparar um composto | |
| BRPI0920180A2 (pt) | Composto, uso de um composto, método para tratar uma infecção bacteriana em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto | |
| WO2010063996A3 (en) | Antibacterial compounds | |
| PL2748165T3 (pl) | Pochodne 1,6-diazabicyklo[3,2,1]oktan-7-onu i ich zastosowanie w leczeniu zakażeń bakteryjnych | |
| BRPI1013705A2 (pt) | compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica | |
| BRPI0823271A2 (pt) | Chip de dna, kit para detecção ou para genotipagem de bactérias que causam doenças sexualmente transmitidas, genotipagem de resistência a fármacos antibacterianos e método de detecção ou de genotipagem das mesmas. | |
| BRPI0912292A2 (pt) | composições e métodos para o uso de células no tratamento do tecido cardíaco. | |
| BRPI0923821A2 (pt) | "dispositivo para cultura de algas e/ou de microorganismos para o tratamento de um efluentes e de uma biofachada" | |
| BRPI0913300A2 (pt) | composto, processo para o preparo e uso do mesmo, método de tratamento de infecção bacteriana em um animal, e, composição farmacêutica. | |
| IL211120A (en) | Compound, tetracycline converted at position 7c with fluorine, a pharmaceutical preparation containing it and its use in the preparation of drugs for the treatment of bacteria-caused infection | |
| BRPI0910686A2 (pt) | células perivasculares do cordão umbilical humano geneticamente modificadas para a profilaxia contra agentes biológicos e químicos ou para o tratamento dos mesmos. | |
| EP2702142A4 (en) | METHOD FOR THE USE OF BIOLOGICAL ACTIVE SUBSTANCES WITH LIVING OR RESTING FORMS OF BACTERIA AND OTHER ORGANISMS IN THE TREATMENT OF INFECTIONS, INFLAMMATORY DISEASES AND OTHER DISORDERS OF THE DISTAL THIN DRAIN AND THICK DARM | |
| FR2898603B1 (fr) | Nouveaux polyurethanes, compositions les comprenant et procede de traitement cosmetique | |
| BRPI0722054A2 (pt) | Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico. | |
| BRPI0919285A2 (pt) | Dispositivo para cultivo/exposição, especialmente para culturas de células e/ou de bactérias. | |
| BRPI0915471A2 (pt) | composto, composição farmacêutica, métodos de inibir dna girase bacteriana e/ou topoisomerase bacteriana iv, para produzir um efeito antibacteriano em um animal de sangue quente e para tratar uma infecção bacteriana em um animal de sangue quente, e, uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |